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1. Introduction 
In human physiology, proteins at all times are synthesized, processed, degraded and post-
translationally modified to varying degrees and at different rates, for their participations in 
a wide variety of activities to maintain normal functions of the body (Murray et al. 2007). In 
the successful proceedings of all the biological events, signals are consistently received and 
sent via physical contacts between proteins (Murray et al. 2007). The communication 
between proteins or the alternatively called non-covalent protein-protein interactions are 
thereby considered as important as proteins’ own functions (Murray et al. 2007). 
Disruptions of these signaling pathways by either mutational changes or deregulation of 
one of the protein partners would result in a series of diseases (Murray et al. 2007). On the 
other hand, therapeutic approaches based on chemical agents could potentially inhibit 
protein-protein interactions, thereby restoring the balance of signaling pathways, and 
leading to the cure of diseases (Murray et al. 2007). However, it is quite challenging to 
develop chemical agents which can target protein-protein interactions (Arkin et al. 2004; 
Whitty et al. 2006). Unlike the traditional medicinal chemistry approach, in which small 
molecule inhibitors are developed to target the hydrophobic pocket of enzymes / kinases, 
chemical agents are now required to bind to large surfaces of proteins that are usually 
amphiphilic and flexible (Murray et al. 2007). Yet a number of successful stories have been 
reported (Murray et al. 2007). Taking the p53/MDM2 system as an example, the 
p53/MDM2 has been a model system for the inhibition of protein-protein interactions, and 
has been reported to be the targets of a wide variety of inhibitors (Oren 1999; Balint et al. 
2001; McLure et al. 2004; Brooks et al. 2006).  
The tumor suppressor protein p53 is a transcription factor that executes multiple anticancer 
functions. Through its binding to DNA, p53 can initiate the expression of several important 
proteins, which are responsible for DNA repair, induction of growth arrest to hold the cell 
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cycle at the G1/S regulation point, as well as the initiation of apoptosis (Lowe et al. 1993; 
Pellegata et al. 1996; Liu et al. 2001). However, at the normal state, the p53 activity is down-
regulated by the murine double minute 2 protein (MDM2) which binds to the ┙-helical 
transactivation domain near the N-terminus of p53 (Momand et al. 1992; Oliner et al. 1992). 
Cocrystal structure studies revealed that three hydrophobic side chains from Phe19, Trp23, 
and Leu26 of p53 make direct contacts with MDM2 and account for the primary interactions 
(Kussie et al. 1996). The binding of MDM2 not only inhibits p53 DNA-binding activity but 
also induces the proteosomal degradation of p53 (Haupt et al. 1997; Kubbutat et al. 1997) . In 
the event of stress, p53 protein is phosphorylated, which leads to a much reduced affinity 
between p53 and MDM2, and thereby reactivating p53 (Jimenez et al. 1999). Nonetheless, 
MDM2 is constantly over-expressed in tumor cells, which significantly blocks the activation 
of p53 pathway even during stress conditions, thereby leading to the uncontrolled tumor 
cell proliferation (Momand et al. 1998). The overproduction of MDM2 makes tumors less 
susceptible to programmed cell death and apoptosis as a result of chemotherapy and other 
cancer therapy. Hence, the disruption of MDM2/p53 interaction in tumor cells should 
stabilize p53, preventing it from degradations, and initiating a cascade of p53 pathways to 
eventually sensitize the tumor cells to death (Murray et al. 2007). To date, targeting the 
MDM2/p53 interaction has become an emerging therapeutic approach in anticancer 
treatment. Numerous efforts have been taken for the development of inhibitors such as 
natural products (De Vincenzo et al. 1995; Stoll et al. 2001; Duncan et al. 2003; Tsukamoto et 
al. 2006), small molecules (Zhao et al. 2002; Galatin et al. 2004; Vassilev et al. 2004; Ding et al. 
2005; Grasberger et al. 2005; Hardcastle et al. 2006), and oligomers (Alluri et al. 2003; Hara et 
al. 2006; Robinson 2008; Hayashi et al. 2009; Michel et al. 2009; Bautista et al. 2010). 
Compared to small molecule approach, oligomers are easily programmable and are readily 
synthesized by solid phase synthesis. It is also believed that the larger size of oligomers 
relative to small molecules may bring them additional advantages to contact more protein 
surface area, which will lead to enhanced binding affinity (Murray et al. 2007).  
However, oligomers made of natural peptides are subjected to biodegradations and are also 
immunogenic in vivo, which limit their practical applications, but on the other hand 
underscore the need for unnatural peptides (Patch et al. 2002). Peptidomimetics are a class 
of non-natural peptide mimics using the artificial backbones to mimic peptides’ primary and 
secondary structures (Wu et al. 2008). Compared to traditional peptides, peptidomimetics 
have great proteolytic and metabolic stability and are believed to be less immunogenic, also 
with an enhanced bioavailability (Patch et al. 2002; Goodman et al. 2007; Wu et al. 2008). The 
development of peptidomimetics to disrupt MDM2/p53 has led to a diverse set of 
oligomers such as ┚-peptides (Seebach et al. 1996; Cheng et al. 2001; Kritzer et al. 2005), ┛- 
and ├-peptides (Arndt et al. 2004; Trabocchi et al. 2005; Kumbhani et al. 2006), ┙/┚-peptides 
(Horne et al. 2008; Horne et al. 2009), azapeptides (Graybill et al. 1992; Lee et al. 2002), ┙-
aminoxy-peptides (Li et al. 2008), sugar-based peptides (Risseeuw et al. 2007; Tuwalska et al. 
2008), peptoids (Simon et al. 1992), oligoureas (Boeijen et al. 2001; Violette et al. 2005), 
polyamides (Dervan 1986), and phenylene ethynylenes (Nelson et al. 1997), etc. Nonetheless, 
the development of peptidomimetics is far less straightforward, with the major limit lying in 
the availability of framework (Goodman et al. 2007). The search for peptidomimeitcs of a 
variety of backbones remains crucial in the research of peptide mimics, which would result 
in different classes of oligomers with diverse structures and functions (Goodman et al. 2007; 
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Horne et al. 2008; Gellman 2009). The development of new peptidomimetics would also 
facilitate the identification of novel therapeutic agents and help the understanding of 
protein folding and functions by using peptidomimetic probes, all of which are important to 
the progress in modern chemical biology research (Goodman et al. 2007; Horne et al. 2008; 
Gellman 2009).  
2. Development of AApeptides  
In the attempt to search for new peptide mimics for drug discovery and protein mimicry, we 
recently described a novel class of peptidomimetics termed “AApeptides”, which is derived 
from N-acylated-N-aminoethyl amino acids that has been previously used as the building 
block for PNA (Winssinger et al. 2004; Dragulescu-Andrasi et al. 2006; Debaene et al. 2007). 
Compared to natural peptides, the repeating unit of the AApeptide is structurally similar to 
two adjacent residues of ┙-peptide, in which there are two side chains, one from the regular 
┙-amino acid side chain, while the other one from a carboxylic acid residue appended to the 
tertiary amide nitrogen. Depending on the relative position of ┙-amino acid side chain, there 
are two types of AApeptides. The one with ┙-amino acid side chain at the ┙ position is 
called ┙-AApeptide (Hu et al. 2011), while the other one with side chain at the ┛ position is 































α-AApeptide γ-AApeptide  
Fig. 1. Structures of a ┙-peptide and the corresponding AApeptides.  
Both type of AApeptides project the same number of functional groups as conventional 
peptides with backbones of the same length. In addition, all the nitrogen atoms of 
AApeptides are involved in either secondary or tertiary amide bonds, in a way similar to 
natural ┙-peptide. Taken together, such AApeptides are designed to mimic the distance 
relationships and relative positions of amino acid side chains of natural peptides, so that 
they can reserve some functions of conventional peptides. It is also noteworthy that, even 
though AApeptides can mimic the structure as well as some activities of natural peptides, 
they are still different in backbone and should possess distinct hydrogen bonding properties 
and conformational flexibilities. The backbone of AApeptide is more flexible, with involved 
tertiary amide bonds potentially in cis/trans conformations, suggesting that the direct inter-
conversion of sequences between AApeptides and natural peptides may not result in the 






3. Development of AApeptides for inhibition of p53/MDM2 interaction 
For proof of concept, we demonstrated the facile synthesis and potential bioactivities of 
AApeptides by developing AApeptide based inhibitors of the p53/MDM2 model system, 
which has been a testing ground for freshly developed peptidomimetics of novel 
frameworks.  
3.1 Design of AApeptide sequences 
Previous reports indicated that synthetic agents displaying hydrophobic side chains of 
Phe19, Trp23, and Leu26, and in the orientation mimicking the array of these amino acids in 
p53 should compete with p53 in occupying the MDM2 cleft (Murray et al. 2007). Based on 
these findings, we designed four ┙-AApeptides and three ┛-AApeptides to mimic the 

























































































Fig. 2. ┙-AApeptide sequences designed for inhibition of p53 / MDM2 interaction. Figure is 
adapted from (Hu et al. 2011). 
These AApeptides bear either some or all of the functional side chains of the three amino 
acids (Phe19, Trp23, and Leu26), which are designed to be the amino acid side chains at 
either ┙ (for ┙-AApeptides) or ┛ positions (for ┛-AApeptides). The other functional groups 
were randomly chosen, with most of them appended to the nitrogens of AApeptides 
through the formation of tertiary amide bonds.  
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Fig. 3. ┛-AApeptide sequences designed for p53/MDM2 disruption. Figure is adapted from 
(Niu et al. 2011).  
3.2 Synthesis of AApeptides  
In our initial attempt, we tried to synthesize AApeptides on solid phase resins through a 
direct sub-monomer strategy, in which the functional groups were introduced to the 
sequence step by step (Figure 4). Unfortunately, the presence of multiple secondary amines 
in the peptide backbone led to a constant over-alkylation during the reductive amination 
step. As a result, we only obtained a mixture of unidentified products after several coupling  
 
Fig. 4. Initial unsuccessful attempt to synthesize AApeptides on solid phase. Figure is 





































































cycles, as observed on HPLC after the cleavage of products from solid phase. We then 
carried out an alternative “monomer building block” strategy, in which building block was 
first synthesized in solution phase, and then assembled following the same procedure of 
standard solid phase synthesis of conventional peptides. In this route, AApeptide building 
blocks are readily prepared using commercially available agents at low cost.  
For the synthesis of ┙-AApeptide building block (Figure 5), the carboxylic acid of amino acid 
was first protected to form the amino acid benzyl ester (A) or the amino acid tert-butyl ester 
(B). The resulting amino acid esters were then reacted with Fmoc-amino ethyl aldehyde by 
reductive amination to form secondary amines 2, which were subsequently acylated with 
functional groups R1. The coupling products 3 were finally deprotected with hydrogenlysis to 
remove the benzyl protecting group, or with trifluoroacetic acid to remove the tert-butyl 
protecting group. For the synthesis of ┛-AApeptide building block (Figure 6), glycine benzyl 
ester was reacted with Fmoc-amino aldehydes through reductive amination, and the resulting 
intermediates 2 was subsequently acylated with carboxylic acid ended functional groups to 
form the coupled intermediate 3. After a hydrogenation step, the desired ┛-AApeptide 
building blocks 4 were finally obtained. For both ┙ and ┛ AApeptides, a diverse set of 
conjugation conditions for the preparation of intermediates 3 were investigated. It was found 
that the use of activation agents such as HBTU/HOBt, DIC/HOBt, or PyBOP can provide the 
desired products in poor yields, and only when intermediate 2 was conjugated with a few 
types of carboxylic acids. After many trials, the coupling with oxohydroxybezotriazole / DIC 
emerged as the most efficient and can catalyze the successful conjugations of most carboxylic 
acids. It is also noteworthy that the derivatization of AApeptides is virtually limitless, since 
there are countless carboxylic acids available for acylation of nitrogen atom in the backbone. 
This specific feature allows the rapid generation of AApeptide library, which literally should 
have much more diversity than those libraries based on regular peptides, thereby expanding 
the versatility of oligomer libraries for potential applications in high-throughput screening 
based drug discovery and chemical biology research. With the prepared building blocks in 
hand, the solid phase synthesis of AApeptides was carried out on resins in a simple and highly 
efficient way. The sequences were finally obtained over 80% yield in crude and were purified 
by HPLC to achieve purities over 95%. Their identities were further confirmed by MALDI-
mass spectrometry. 
 
Fig. 5. Synthesis scheme of ┙-AApeptide building block. a) Fmoc-amino ethyl aldehyde, 
NaBH3CN, overnight. b) R1CH2COOH, DhBtOH/DIC, overnight. c) Pd/C, H2 for A; 50% 
TFA/CH2Cl2 for B. Figure is adapted from (Hu et al. 2011). 
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Fig. 6. Synthesis scheme of ┛-AApeptide building block. Figure is adapted from (Niu et al. 
2011).  
3.3 ELISA assay of AApeptides for inhibition of p53/MDM2 interaction  
These AApeptides were then tested by the ELISA assay for their inhibition of p53/MDM2 
protein-protein interaction. Generally the ELISA plate was coated with p53, and then 
incubated with the mixture of MDM2 protein and AApeptide for one hour. The p53 bound 
MDM2 protein was then detected by MDM2 antibody and a secondary antibody conjugated 
with the horseradish peroxidase, which later on reacted with the TMB peroxidase substrate 
to manifest a yellowish color after acid quenching. The color intensity was monitored by 
absorbance at 450nm, the extent of which is directly proportional to the amount of bound 
MDM2 protein, and also reversely correlated to the inhibiting efficiency of AApeptide. The 
readings for each sample were then plotted against the concentration of ┙-AApeptide 
(Figure 7) or ┛-AApeptide (Figure 8). Almost all AApeptides inhibit the p53-MDM2 binding 
when they are administrated at high concentrations.  
Based on the plots of each peptide in Figure 7 and 8, the related IC50 values were calculated 
and summarized in Table 1. The published IC50 value of the wide type p53-drived peptide 
(Garcia-Echeverria et al. 2000) was also included for comparison. For ┙-AApeptide, α-AA4 
is the most prominent one, with an IC50 of 38µM, which is comparable to the previously 
reported ┚-peptides and peptoids (Knight et al. 2002; Kritzer et al. 2004; Hara et al. 2006), 
and is only 4-5 fold less potent than the reported p53-drived wild type peptide (Garcia-
Echeverria et al. 2000). Consistent to previous reports (Kussie et al. 1996), the preliminary 
structure and activity relationship (SAR) study here suggests that the inclusion of 
functionalities of the three key amino acids “Phe, Typ, and Leu” are important to maintain 
the strong binding affinity, which are present in all sequences but α-AA1. Compared to α-
AA2, the change of Leu to Val in α-AA1 decreases the binding affinity to at least 10-fold. 
Further, that observation of α-AA4’s much higher activity than α-AA2 indicates that better 
activities are possessed by longer sequences. The longer sequence may possibly have a 











































































Fig. 7. Plots of ELISA assay for the inhibition of p53-MDM2 interaction by ┙-AApeptides 





























Fig. 8. Plots of ELISA assay for the inhibition of p53-MDM2 interaction by ┛-AApeptides. 
Figure is adapted from (Niu et al. 2011). 
 
AApeptides IC50 (µM) 
┙-AA1 >1000 
┙-AA2 120 ± 10 
┙-AA3 120 ± 16 
┙-AA4 38 ± 8 
┛-AA1 > 400 
┛-AA2 120 ± 15 
┛-AA3 50 ± 8 
p53-derived peptide (Ac-QETFSDLWKLLP) 8.7 
Table 1. ELISA results of AApeptides for the disruption of p53/MDM2. 
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Finally, since α-AA4 differs from α-AA3 in only one residue, the side chains not involved 
in the recognition of MDM2 may also play a substantial role in the binding event. In this 
case, the Phe side chain of α-AA3 may be either in the hydrophobic binding cleft, or near 
the binding domain, clashing with the residues of MDM2 and thereby raising up their 
binding energy. For ┛-AApeptides, γ-AA3 turns out to be the most effective inhibitor, 
with an IC50 value of 50µM, which is comparable to the most active ┙-AApeptide and is 
also only a few fold less active than p53-derived peptide (Garcia-Echeverria et al. 2000). 
Compared to the others, replacement of Phe by Leu in γ-AA1 peptide results in a 
significant loss of activity. Whereas γ-AA2 and γ-AA3 both have the required “Phe, Typ, 
and Leu”, the slight difference of their side chain functionalities between Phe and Leu 
results in more than two fold difference in activity, suggesting that even the side chains 
are also involved in the binding pocket. This observation is similar to the situation of ┙-
AA peptides.  
3.4 Computer modelling for bioactive AApeptides 
The ELISA results were further confirmed by preliminary computer modeling studies 
(Figure 9 and 10), which shows that the side chains of Phe, Trp and Leu in the energy-
minimized structures of both α-AA4 and γ-AA3 are able to overlap perfectly with those 
residues in the helical domain of natural peptide p53, indicating that α-AA4 and γ-AA3 
should be able to mimic the recognition of p53 to MDM2 very well. Compared to γ-AA3, α-





Fig. 9. Energy minimized (MM2) structures of α-AA4 (green colored) and amino acids 17-29 
of p53 helical domain (yellow colored). α-AA4 is shown as sticks, and the three critical 
residues (Phe19, Trp23, and Leu 26) in p53 responsible for binding to MDM2 are also 







Fig. 10. Energy minimized (MM2) structures of γ-AA3 (blue colored) is superimposed with the 
amino acids 17-29 of p53 helical domain (green colored). Three critical residues (Phe19, Trp23, 
and Leu 26) in p53 responsible for binding to MDM2 are presented in as sticks and colored in 
red. γ-AA3 is shown as the wire frame presentation. Figure is adapted from (Niu et al. 2011).  
3.5 Summary  
Taken together, these results demonstrated AApeptides as a novel class of peptidomimetics. 
It is also noteworthy that both classes of AApeptides bear excellent selectivity, with different 
sequences giving different activities, instead of a random interaction with proteins. For 
example, α-AA4 is the strongest inhibitor among all the demonstrated ┙-AApeptides, while 
α-AA1 is a poor inhibitor, and α-AA2, α-AA3 are weak inhibitors. Similarly, γ-AA3 appears 
to be the best inhibitor, while γ-AA1 turns out to be the worst.  
Detailed structure-activity relationship studies for AApeptides with various lengths and 
distribution of functional groups along the backbone are currently ongoing, which should 
provide valuable information for rational design of AApeptide library for drug discovery 
and chemical biology research. Generally, much more potent AApeptide derivatives are 
expected with the stabilization of secondary structure, introduction of halogen atoms, and 
computer modeling-aided design (Hara et al. 2006; Murray et al. 2007; Michel et al. 2009).  
4. Stability of AApeptides  
One significant advantage of peptidomimetics is the superior resistance to proteolysis, 
owing to their unnatural backbones. To find out the stability of our AApeptides in this 
regard, representative sequences of ┙- and ┛- AApeptides (α-AA3, γ-AA3) were incubated 
with proteases at the concentration of 0.1 mg/mL in 100 mM pH 7.8 ammonium bicarbonate 
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buffer for 24 hours. α-AA3 was mixed with chymotrypsin, trypsin, and pronase, 
respectively; and γ-AA3 was mixed with chymotrypsin, thermolysin, and pronase, 
respectively. All the reaction mixtures were then analyzed by HPLC. The retention time and 
integrations of eluted peaks were compared with those of peaks representative of the 
starting materials.  
As shown in figure 11 and figure 12, whereas conventional peptides are susceptible to 
proteolysis, especially by chymotrypsin and pronase, both α-AA3 and γ-AA3 are highly 
resistant to enzymatic hydrolysis within 24 hours. There are, however, a small shoulder 
observed for both types of AApeptides at 37oC with or even without incubation with 
proteases, which takes up less than 5% of the total volume and is presumably due to the 
isomerization of the syn/anti tertiary amide bonds in the peptide backbones.  
 
┙-AApeptide 3 Control natural peptide 
 
RT + buffer 
 
RT + buffer 
 
37 oC + buffer 
 
37 oC + buffer 
 
RT + buffer + Trypsin 
 






┙-AApeptide 3 Control natural peptide 
 
RT + buffer + Chymotrypsin 
 
RT + buffer + Chymotrypsin 
 
37 oC + buffer + Pronase 
 
37 oC + buffer + Pronase 
Fig. 11. Analytical HPLC spectra of α-AA3 and control ┙-peptide after their incubations 
with different proteases. Figure is adapted from (Hu et al. 2011). 
γ-AApeptide 3 (37 oC) 
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γ-AApeptide 3 + thermolysin (37 oC) 
γ-AApeptide 3 + pronase (37 oC) 
Fig. 12. Incubation of γ-AA3 with different proteases. Figure is adapted from (Niu et al. 2011).  
5. Conclusions 
In conclusion, we have developed a new class of peptidomimetics – the AApeptides that can 
have amino acid side chains at either ┙-, or ┛-position. This family of peptides can be readily 
synthesized on solid phase by standard monomer building block approach, using ┙ or ┛- 
substituted N-acylated-N-Fmoc-amino ethyl amino acid building blocks. Given the 
availability of countless types of carboxylic acids, the AApeptides are amenable to potential 
derivatizations with a wide variety of side chains in a simple and straightforward manner, 
indicating its promising applications in library based drug screening. The preliminary 
results show that AApeptides possess significant bioactivities including the mimicry of p53 
to successfully inhibit the p53/MDM2 protein-protein interaction, the selectivity in binding 
MDM2 protein, and the excellent stability towards enzymatic degradations. Hence, it is 
conceivable that a continuing development of sequence-specific AApeptides would enrich 
the current types of functional peptidomimetics, and expand the applications of peptide 
mimics in biomedical research including the modulation of protein-protein interactions. 
Future work will involve the systematic studies using X-ray crystallography, Circular 
Dichroism (CD), and 2D-NMR to understand the structure requirements of AApeptides to 
adopt predicted conformations, which will help the design of functional AApeptides. More 
specifically, the optimizations of AApeptide sequences to achieve a better inhibition of 
p53/MDM2 interaction as well as other carbohydrates/proteins/nucleic acids interactions 
are also urgent and are currently under investigation.  
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